Piflufolastat

CHEMBL4299851 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
442.4 g/mol
LogP
-0.1
Phase
4

Piflufolastat is a small molecule ligand targeting prostate-specific membrane antigen (PSMA) that is used as a radiotracer for PET imaging in prostate cancer and is under investigation for targeted radiotherapy applications in breast and pancreatic cancer. It binds with high affinity to PSMA, enabling highly specific tumor localization for diagnostic imaging and potentially for targeted radionuclide therapy.

Peso molecular

442,4000 g/mol

LogP

-0,10

TPSA

195,00 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Mecanismo de acción

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)c1ccc(F)nc1)C(=O)O)C(=O)O

InChI

InChI=1S/C18H23FN4O8/c19-13-6-4-10(9-21-13)15(26)20-8-2-1-3-11(16(27)28)22-18(31)23-12(17(29)30)5-7-14(24)25/h4,6,9,11-12H,1-3,5,7-8H2,(H,20,26)(H,24,25)(H,27,28)(H,29,30)(H2,22,23,31)/t11-,12-/m0/s1

Molecular Formula

C18H23FN4O8

HBD / HBA

6 / 10

Enlaces Rotables

13

Átomos Pesados

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

Piflufolastat is a small molecule ligand targeting prostate-specific membrane antigen (PSMA) that is used as a radiotracer for PET imaging in prostate cancer and is under investigation for targeted radiotherapy applications in breast and pancreatic cancer. It binds with high affinity to PSMA, enabling highly specific tumor localization for diagnostic imaging and potentially for targeted radionuclide therapy.

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Yes, Piflufolastat is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4299851. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 71532123. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.